Exton released some market research reports evaluating the nephrology market in Europe. The pool containing opinions of over 200 European nephrologists was made in May and June 2010. The doctors were asked about their methods of treating renal anemia and bone disturbances.
European nephrologists showed a more conservative approach about treating this disease. They don’t like erythropoiesis-stimulating agents (ESAs). Most of them expect less aggressive behavior of the body when using TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy). The brand was adopted quickly, especially in Germany.
Most specialists are using non-calcium phosphate these days, as the trend continues upward. Those nephrologists that begin the treatment with calcium-based agents will also use Genzyme’s sevelamer or Shire’s lanthanum. Phosphorus is considered more important than calcium, particularly for the dialysis patients. The leading cause of calcification is considered hyperphosphatemia, compared to other factors. Nephrologists continued to use Mimpara for the next six months, as other markets suggested the poor gastrointestinal tolerability.
The study also showed that European nephrologists are reluctant when it comes to new treatments. Most of them will expect that chronic kidney disease patients (non-dialysis) will expect an increase in the level of intravenous iron. ESAs with biosimilar are popular in Germany, while the nephrologists in the United Kingdom will prefer Mimpara, although the costs associated with this medicine are greater. Mimpara is considered a great alternative as long as the patient could tolerate it. Other European markets are reluctant to this treatment because of the poor gastrointestinal tolerability. One third of nephrologists will still choose Mimpara for the effect of the lowering calcium.
BioTrends Research Group provides market research for some major pharmaceuticals manufacturers on several pharmaceutical markets. Decision Resources has a cohesive portfolio of companies that offers best class value information.